Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients-Reference-Cited by-同舟云学术

Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients

Published:2022-02 Issue:2 Volume:3 Page:104-118.e4
ISSN:2666-6340
Container-title:Med
language:en
Short-container-title:Med

Author:

Khoo Nicholas Kim Huat^ORCID,Lim Joey Ming Er^ORCID,Gill Upkar S.,de Alwis Ruklanthi^ORCID,Tan Nicole^ORCID,Toh Justin Zhen Nan,Abbott Jane E.^ORCID,Usai Carla^ORCID,Ooi Eng Eong^ORCID,Low Jenny Guek Hong,Le Bert Nina^ORCID,Kennedy Patrick T.F.,Bertoletti Antonio^ORCID

Publisher

Elsevier BV

Subject

General Medicine

Reference57 articles.

1. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK;Voysey;Lancet,2021

2. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial;Folegatti;Lancet,2020

3. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine;Polack;N. Engl. J. Med.,2020

4. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19;Sadoff;N. Engl. J. Med.,2021

5. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar;Chemaitelly;N. Engl. J. Med.,2021

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety, Effectiveness and Immunogenicity of heterologous mRNA-1273 Boost after Prime with Ad26.COV2.S among Healthcare Workers in South Africa: the single-arm, open-label, Phase 3 SHERPA Study;2024-06-11

2. Long-term trial of protection provided by adenovirus-vectored vaccine expressing the PPRV H protein;npj Vaccines;2024-06-03

3. Hamster Model of Severe COVID-19 Demonstrates Differential Efficacy of first Licensed Western Vaccines in the Absence of Immunopathogenesis;2024-04-24

4. Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants;PLOS Global Public Health;2024-04-11

5. Characteristics and clinical outcomes of patients with pre-delta, delta and omicron SARS-CoV-2 infection in Indonesia (2020–2023): a multicentre prospective cohort study;The Lancet Regional Health - Southeast Asia;2024-03